Eugia Pharma Receives USFDA Tentative Approval for Plerixafor Injection 24 mg/1.2 mL
Published: July 20, 2022
Eugia US is pleased to announce that the company has received tentative approval from the US Food & Drug Administration (USFDA) to manufacture and market Plerixafor Injection 24 mg/1.2 mL.
Indications for this product include:
- Indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM).
Refer to package insert for full prescribing information.